ArticleMedicine2026
Circulating fatty acid profiles and risk of pulmonary arterial hypertension: Evidence from a large prospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fatty acids (FAs) have cardioprotective properties. However, their role in the development of pulmonary arterial hypertension (PAH) has not been thoroughly examined. This study aimed to investigate the relationship between circulating FA profiles and the risk of PAH. Data from the UK Biobank were used to assess the association between 8 circulating FAs and PAH risk. Cox proportional hazards regression models estimated hazard ratios and 95% confidence intervals, with stratified analyses conducted across demographic and clinical subgroups. Restricted cubic spline models were employed to explore potential nonlinear dose-response relationships, while accelerated failure time models assessed the effect of FA levels on the timing of PAH onset. Higher levels of all 8 FAs were linked to a reduced risk of PAH, with the strongest inverse associations observed for docosahexaenoic acid, omega-3, and polyunsaturated fatty acids (hazard ratio range: 0.76 to 0.85, all P < .001). Restricted cubic spline analysis revealed nonlinear relationships between docosahexaenoic acid, omega-3 FAs, and PAH risk. Additionally, accelerated failure time models showed that participants in the highest quartile of FA concentrations experienced a delay in PAH onset by approximately 60 to 120 months compared to those in the lowest quartile. Elevated circulating FA levels were associated with a lower risk of incident PAH, with consistent patterns across most demographic and clinical subgroups. These findings provide novel population-based evidence supporting the potential of FAs as biomarkers for PAH prevention and therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.